logo
CGTN Releases Interview Video Highlighting Coral Reef Crisis in the South China Sea

CGTN Releases Interview Video Highlighting Coral Reef Crisis in the South China Sea

BEIJING, June 25, 2025 (GLOBE NEWSWIRE) — Recently, in a report by Huang Yue, CGTN focused on the coral reef crisis in the South China Sea through an interview video that drew global attention. Ding Zhifu, a fisherman from Tanmen Port, Hainan, shared in the interview the water there was crystal blue. The coral reefs below were clearly visible. While now fish catch has dropped. Coral bleaching is damaging the habitats, and some foreign fishermen using explosives has made it even worse. The video, leveraging fishermen's testimonies, scientific monitoring, and international data, uncovers an ecological alert amid climate change and human destruction, mirroring the existential crisis of the South China Sea's coral reef ecosystem.
The South China Sea, as blue granary for numerous fishermen, is ecologically threatened. The International Coral Reef Initiative's data shows that over 84% of global coral reefs have been affected by the fourth mass bleaching event, with significant damage in China's waters. In an interview, Professor Yang Hongqiang from the South China Sea Institute of Oceanology emphasized that the sharp decline in coral reef diversity has pushed many species to the brink of extinction. Seawater warming disrupts the coral-algae symbiosis, depriving corals of nutrients and hastening their death. Moreover, severe storms, ocean acidification, and Crown-of-Thorns starfish outbreaks are exacerbating the crisis.
Meanwhile, misleading media reports hinder ecological conservation efforts. Some media outlets have sensationalized claims that China uses coral fragments to build artificial islands. However, CGTN's interview with relevant researchers revealed that most sandbars are naturally formed by wave-accumulated coral debris. Professor Yang Hongqiang presented monitoring records from 2016 to 2018, confirming that sandbars naturally shift after storms, not being artificially constructed.
As a pivotal player in global biodiversity conservation, China offers a Chinese proposal for coral reef restoration. Professor Huang Hui's team, known as the Coral Mother, has planted nearly 400,000 coral plants and cultivated over 100 species across a 30-hectare sea area in Hainan. Additionally, China promotes coral reef monitoring and restoration through artificial intelligence, underwater sensors, and international cooperation.
Immediate action on climate change is crucial to save the South China Sea's key ecosystems. Australian coral biologist Jennifer Matthews warns that time is of pressing, only with global attention to underwater ecological warnings can coral reefs' future be reversed.
China Global Television Network Huang Yue
[email protected] 17092894596
https://www.cgtn.com/

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP
ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

Business Upturn

timean hour ago

  • Business Upturn

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025 Marks the first submitted Clinical Trial Application (CTA) advancing ProQR's Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) — ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases. 'The submission of this CTA marks a significant milestone for ProQR, representing the first to advance our Axiomer RNA editing platform and pipeline into clinical development,' said Cristina Lopez Lopez, MD, PhD Chief Medical Officer of ProQR. 'This step brings us into the clinic with AX-0810 as we initiate a Phase 1 study to evaluate safety and target engagement in healthy volunteers. Cholestatic liver diseases represent an area of high unmet medical need and by targeting NTCP, AX-0810 introduces a novel therapeutic approach underpinned by human genetics and compelling preclinical data.' The proposed Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AX-0810 in healthy adult volunteers. The study will also explore biomarkers to assess early signals of target engagement. Pending regulatory clearance, the study is expected to commence at a single site in the Netherlands with initial data anticipated in Q4 2025. About AX-0810 AX-0810 is an investigational GalNac-delivered RNA editing oligonucleotide designed to treat cholestatic liver disease by targeting NTCP. These diseases are driven by toxic bile acid accumulation due to impaired bile flow, leading to progressive liver damage. AX-0810 offers a novel therapeutic approach by selectively modulating NTCP function, which decreases bile acid reuptake into the liver. This mechanism is supported by human genetics data showing that naturally occurring NTCP variants safety reduce bile acid reuptake, reinforcing the potential of NTCP modulation by ADAR-mediated RNA editing to improve liver health and alter the course of cholestatic disease. About Axiomer™ ProQR is pioneering a next-generation RNA base editing technology called Axiomer™, which could potentially yield a new class of medicines for diverse types of diseases. Axiomer 'Editing Oligonucleotides', or EONs, mediate single nucleotide changes to RNA in a highly specific and targeted way using molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is translated as a Guanosine (G) – correcting an RNA with a disease-causing mutation back to a normal (wild type) RNA, modulating protein expression, or altering a protein so that it will have a new function that helps prevent or treat disease. About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Learn more about ProQR at Forward Looking Statements for ProQR This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as 'continue,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'goal,' 'intend,' 'look forward to', 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our business, ; our Axiomer™ RNA editing technology platform, including the continued development and advancement of our Axiomer platform, the advancement of AX-0810 to clinical trials, including the timing of, and our ability to obtain regulatory clearance; our expectations regarding the initiation of the planned Phase 1 clinical study of AX-0810 in the Netherlands, including our ability to recruit for and complete the study, and the anticipated timing of initial data in Q4 2025; the plan, timing, progress and results of our preclinical studies, planned clinical trials and other development activities, including the release of data related thereto, and the potential of our technologies and product candidates. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our most recent annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners whose operations and activities may be slowed or halted shortage and pressure on supply and logistics on the global market, economic sanctions and international tariffs; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations and predictability of timely enrollment of subjects and patients to advance our clinical trials and maintain their own operations; our reliance on contract manufacturers or suppliers to supply materials for research and development and the risk of supply interruption or delays from suppliers or contract manufacturers; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to initiate and continue to advance and progress our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. high inflation, rising interest rates, tariffs and potential for significant changes in U.S. policies and regulatory environment. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. ProQR Therapeutics N.V. Investor and media contact:Sarah KielyProQR Therapeutics N.V.T: +1 617 599 6228 [email protected] or Investor contact: Peter KelleherLifeSci AdvisorsT: +1 617 430 7579 [email protected]

Alert: There's a Lost Spaceship in the Ocean
Alert: There's a Lost Spaceship in the Ocean

Yahoo

time6 hours ago

  • Yahoo

Alert: There's a Lost Spaceship in the Ocean

In science fiction, we often have the trope of a spacecraft becoming lost in space — but what about being lost at sea? That's what happened this week with an eight-foot-wide experimental spacecraft flown by a European aerospace outfit called The Exploration Company, according to a company statement on LinkedIn. When the vehicle came back to Earth, mission control lost contact with the craft when it entered the ocean. "The capsule was launched successfully, powered the payloads nominally in-orbit, stabilized itself after separation with the launcher, re-entered and re-established communication after black out," the company wrote on Tuesday. "But it encountered an issue afterwards, based on our current best knowledge, and we lost communication a few minutes before splash down," the statement continued. "We are still investigating the root causes and will share more information soon." The unmanned spacecraft, dubbed Mission Possible — a test capsule for a future cargo- and astronaut-carrying craft — was successful in that it was able to shoot into space, make an orbit around Earth, survive its fiery descent back home, and establish contact with mission control. Of course, that was all before it got lost at sea. Monday afternoon was its launch from the Vandenberg Space Force Base in Santa Barbara County, California, according to Ars Technica. It hitched a ride on a SpaceX mission that also launched 70 payloads, along with human remains for a space memorial. The Exploration Company leadership is calling it a success, saying it proved that putting together a mission using low-cost, off-the-shelf parts — such as parachutes from SpaceX's Dragon — can result in a successfully launched capsule. Mission Possible was built at a cost of about $20 million. Possible next steps for the company include building a more advanced and reusable cargo vehicle called Nyx, according to Ars, which could eventually carry humans back and forth between Earth and the Moon. More on spacecrafts: Chinese Spacecraft Accused of Dumping Experimental Fuel in Streak Seen Across American Sky

Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon
Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon

Business Upturn

time8 hours ago

  • Business Upturn

Food-Derived Longevity Supplement Primeadine® GF Launches at Erewhon

SHERIDAN, Wyo., June 26, 2025 (GLOBE NEWSWIRE) — Oxford Healthspan , a female-founded company dedicated to bringing food-derived longevity compounds to market, announces the launch of Primeadine® GF, its gluten-free spermidine supplement for healthy aging, at Erewhon, an independent, family-owned Certified B Corp and Certified Organic retailer with 10 locations across Southern California . Spermidine is a naturally occurring molecule that activates autophagy — a mechanism that mimics the effects of fasting by clearing out damaged cells and encouraging the regeneration of healthier ones. It also targets other key drivers of aging, including chronic inflammation, mitochondrial and stem cell dysfunction, and gut microbiome imbalances. As we age, the body's natural production of spermidine declines, making us more reliant on plant sources in our diet. Sourced from the longevity islands of Okinawa, Japan, Primeadine GF is a first-of-its-kind, gluten-free spermidine supplement sourced from a unique strain of Okinawan chlorella. It also contains two other autophagy-activating ingredients, nobiletin (from 'Shikuwasa' citrus lime peel) and curcumin (from turmeric). 'We're thrilled to bring Primeadine GF to Erewhon, where customers are deeply intentional about what they put in their bodies,' said Leslie Kenny, CEO and founder of Oxford Healthspan. 'This partnership is especially meaningful because both Oxford Healthspan and Erewhon are rooted in Japanese wellness traditions, from the macrobiotic movement that inspired Erewhon's founding to the Japan-sourced ingredients that power our supplements. We share a commitment to aging well through food-based approaches that honor both science and nature.' Primeadine GF delivers a range of science-backed benefits: Supports cellular renewal Promotes cognitive clarity, hormonal balance, and immune resilience Enhances skin, hair, and nail vitality from the inside out Backed by Oxford scientists and recommended by leading clinicians and nutritionists Tested for pesticides, heavy metals and toxins, and free from fillers and flow agents Primeadine GF is now available at all Erewhon locations across Southern California. Learn more about Primeadine GF at . About Oxford Healthspan Oxford Healthspan is a women-led, science-backed longevity supplement company dedicated to helping people age on their own terms by delivering premium, food-derived longevity supplements that harmonize Eastern wisdom with modern longevity science. With a mission to revolutionize healthy aging, Oxford Healthspan sources only the highest-quality ingredients from Japan to ensure purity, potency, and safety. Learn more at and follow @oxfordhealthspan on Instagram. About Erewhon Erewhon is an independent, family-owned Certified B Corp and Certified Organic Retailer with 10 locations across Southern California. Since 1968, Erewhon has been providing organic, ethically-sourced foods to the communities it serves. It's committed to sourcing healthy, nutrient-dense products, backing local growers and brands, and supporting the environment. Recognized for its uncompromising quality standards and customer service, Erewhon sustains a community centered in caring, curiosity, and positive change. For more information, visit MEDIA CONTACT:Lisa Lazarczyk, LAZ PR Tel: 617.838.7327 or [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store